LifeArc Joins Transatlantic Collaboration to Develop a Treatment for Crimean-Congo Hemorrhagic Fever

LifeArc Joins Transatlantic Collaboration to Develop a Treatment for Crimean-Congo Hemorrhagic Fever

A new transatlantic collaboration between the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and LifeArc will look to develop an affordable and accessible monoclonal antibody therapeutic for Crimean-Congo Hemorrhagic Fever Virus (CCHFV), which could treat and protect thousands of people globally.

Transatlantic Partnership Advances Therapeutic Development for

A groundbreaking international collaboration between the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and LifeArc has been launched, aiming to address a severe unmet need in global infectious disease therapeutics. This partnership is focused on developing an affordable and accessible monoclonal antibody (mAb) treatment targeting Crimean-Congo Hemorrhagic Fever Virus (CCHFV), a tick-borne pathogen responsible for thousan…

Transatlantic collaboration to develop therapeutic for Crimean-Congo Hemorrhagic Fever

A new transatlantic collaboration between the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and LifeArc, a UK-based medical research charity, will look to develop an affordable and accessible monoclonal antibody therapeutic for Crimean-Congo Hemorrhagic Fever Virus (CCHFV), which could treat and protect thousands of people globally. Affordable antibody treatments Dr. Aura Garrison, Dr. Joseph Golden and their colleagues …